Replimune names Emily Hill as CFO; previously CFO of PTC Therapeutics

Replimune Group, Inc.

Appointed Emily Hill as CFO effective Sept 18, 2023; she was previously CFO of PTC Therapeutics.
Base salary $495,000, target bonus 40%, plus 125,000 stock options at $18.00 and 83,330 RSUs, vesting over 4 years.
Termination benefits: 12 months salary plus COBRA; enhanced upon change of control.
Ms. Hill brings 15+ years biotech experience, including roles at PTC, Warner Chilcott, and Genzyme.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Emily Hill

Chief Financial Officer

REPL · Replimune Group, Inc.

Effective: 2023-09-18
Filed: September 19, 2023, 7:59 PM ET

On September 19, 2023, Replimune Group, Inc. (“Replimune”) announced the appointment of Emily Hill as its Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Emily Hill was appointed as Chief Financial Officer at Replimune Group, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On September 19, 2023, Replimune Group, Inc. (“Replimune”) announced the appointment of Emily Hill as its Chief Financial Officer.

View on SEC.gov

Replimune Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-101773

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.